Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765562 | 0.96 | KAT2B (0.39) | KAT2BKMT2AMAPTMEN1HPGD | |
| SCHEMBL10046421 | 0.96 | KAT2B (0.39) | KAT2BKMT2AMAPTMEN1HPGD | |
| SCHEMBL14605533 | 0.95 | ALDH1A1 (0.43) | KAT2BKMT2AMAPTMEN1TSHR | |
| SCHEMBL10046422 | 0.92 | KAT2B (0.36) | KAT2BKMT2AMAPTMEN1HPGD | |
| SCHEMBL765112 | 0.87 | CNR1 (0.33) | — | |
| SCHEMBL764385 | 0.86 | KMT2A (0.36) | KAT2BKMT2AMAPTALDH1A1 | |
| SCHEMBL765094 | 0.85 | KAT2B (0.46) | KAT2BKMT2AMAPTMEN1HPGD | |
| SCHEMBL15423259 | 0.83 | KMT2A (0.37) | KAT2BKMT2AMAPTMEN1HPGD | |
| SCHEMBL764377 | 0.83 | CNR1 (0.31) | — | |
| SCHEMBL765580 | 0.83 | CNR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2325169-A9 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | University Of Virginia Patent Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2325169-A2 | Lisofylline analogues and their pharmeacuetical uses | University Of Virginia Patent Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| WO-2007027719-A2 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | KAT2B 4154/4885KMT2A 2042/4885MAPT 4258/4885 |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | KAT2B 4154/4885KMT2A 2042/4885MAPT 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.